AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2017
Nov 17, 2017
31289_dirs_2017-11-17_99c56cdd-b596-4d55-ae26-e3625700d2ee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-11-16
Reporting Person: HIGGINS JOHN L (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-16 | Common Stock | S | 5269 | $142.53 | Disposed | 143542 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.00 to $143.50, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
M&A Activity
2026
May 18
Interim / Quarterly Report
2026
May 8
Earnings Release
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
M&A Activity
2026
Apr 27
Annual Report
2026
Apr 21